EUVIMEDEUVIMED entdecken
Crossref

Treatment Outcomes for Isoniazid-Resistant Pulmonary Tuberculosis Using a Shorter Regimen at a Tertiary Care Centre from the Western Part of India

Pradeep Chaudhary, Neeraj Gupta, Ramakant Dixit, Rajveer Kuldeep, Ranjeet Meghwanshi

UAPM Journal of Respiratory Diseases and Allied Sciences · 25.02.2026 · 3 (01) · 7-11

DOI: 10.70192/v3.i1.02 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UAPM Journal of Respiratory Diseases and Allied Sciences, online erschienen am 25.02.2026. Verfasst von Pradeep Chaudhary und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug-resistant tuberculosis has been associated with higher rates of morbidity and mortality. A global total of an estimated 4 lakh people with ‘multidrug resistant/rifampicin resistant’ tuberculosis (MDR/RR-TB) were detected and notified in 2023. In India, 63,929 MDR/ RR TB cases were diagnosed, with 23,019 patients diagnosed with isoniazid (H)-mono/poly drug-resistant tuberculosis (DR-TB).

Objective

This study analyses the outcome of ‘Isoniazid Mono Resistance’ Tuberculosis patients and the adverse drug reaction (ADR) among those put on isoniazid (H) mono/poly regimen treatment.Method: ‘Isoniazid-mono-poly’ DR TB regimen duration is 6 to 9 months and started according to drug sensitivity testing (DST) among eligible patients. Follow-ups were done every two months for clinical, bacteriological and radiological parameters. Outcomes observed were cure, treatment completed, treatment failure, died, lost to follow-up, not evaluated, switch to another regimen and transfer out, etc., as per standard protocol.

Results

88 isoniazid-mono/poly patients were enrolled over the last two years. There were 62 male and 26 were females. Outcome for isoniazid mono/poly regimen was cure among 40 (45.5%), treatment completed in 34 (38.6%), lost to follow up in 2 (2.3%), treatment failure in 1 (1.1%), died in 9 (10.2%) and switched to another regimen in 2 (2.3%). The prevalence of katG mutation (High level Isoniazid resistance) was more than inhA (Low level Isoniazid resistance). A more favorable treatment outcome was observed among those with minimal/moderate lung disease compared to those with far advance disease with large cavitation (p = 0.029). This was also in line with better sputum conversion.

Conclusion

Treating isoniazid ‘mono-resistant’ TB patients with levofloxacin, rifampicin, ethambutol, and pyrazinamide (LfxREZ) resulted in satisfactory outcomes and low toxicity. Ruling out the isoniazid drug resistance pattern is important for all bacteriologically confirmed TB cases.

Zitieren

APA

Chaudhary, P., Gupta, N., Dixit, R., Kuldeep, R., & Meghwanshi, R. (2026). Treatment Outcomes for Isoniazid-Resistant Pulmonary Tuberculosis Using a Shorter Regimen at a Tertiary Care Centre from the Western Part of India. UAPM Journal of Respiratory Diseases and Allied Sciences, 3(01), 7-11. https://doi.org/10.70192/v3.i1.02

Vancouver

Chaudhary P, Gupta N, Dixit R, Kuldeep R, Meghwanshi R. Treatment Outcomes for Isoniazid-Resistant Pulmonary Tuberculosis Using a Shorter Regimen at a Tertiary Care Centre from the Western Part of India. UAPM Journal of Respiratory Diseases and Allied Sciences. 2026;3(01):7-11. doi:10.70192/v3.i1.02

BibTeX
@article{Chaudhary2026,
  author = {Chaudhary, Pradeep and Gupta, Neeraj and Dixit, Ramakant and Kuldeep, Rajveer and Meghwanshi, Ranjeet},
  title = {Treatment Outcomes for Isoniazid-Resistant Pulmonary Tuberculosis Using a Shorter Regimen at a Tertiary Care Centre from the Western Part of India},
  journal = {UAPM Journal of Respiratory Diseases and Allied Sciences},
  year = {2026},
  volume = {3},
  number = {01},
  pages = {7--11},
  doi = {10.70192/v3.i1.02}
}
Kostenlos starten →